Canadian Creutzfeldt-Jakob disease incidence remained stable during the coronavirus disease (COVID-19) pandemic
CJD prevalence and characteristics remained stable during COVID-19 despite increased EP-QuIC test submissions. These findings verify that CJD surveillance in Canada remained vigilant during the pandemic and highlight the value of EP-QuIC CSF testing for comprehensive CJD monitoring.
Authors
- Kathy L. Frost (ORCID: https://orcid.org/0009-0005-1083-8899)
- Stephanie A. Booth (ORCID: https://orcid.org/0000-0001-8108-5955)
- Ben A. Bailey-Elkin (ORCID: https://orcid.org/0000-0001-6863-2643)
- Dobrila Todoric
- Clark S. Phillipson
- Dominic M. S. Kielich
- Jessy A. Slota (ORCID: https://orcid.org/0000-0002-9025-8368)
- Vanessa Bergeron
- Lise Lamoureux
- Jennifer Myskiw (ORCID: https://orcid.org/0009-0003-0625-7130)
- Kristen Avery
- Sharon L. R. Simon (ORCID: https://orcid.org/0000-0001-8683-7749)
Institutions
- Public Health Agency of Canada (CA)
- University of Manitoba (CA)
Publication Details
- Journal
- Frontiers in Neurology
- Published
- 2025-12-19
- DOI
- https://doi.org/10.3389/fneur.2025.1729083
- Primary Topic
- Prion Diseases and Protein Misfolding
- Type
- article
- Field-Weighted Citation Impact
- 0.00